Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Universal Vision Biotechnology Co., Ltd. (3218.TWO)
Taipei, TW
Universal Vision Biotechnology Co., Ltd., established in 1992 and based in Taipei, Taiwan, manages a network of eye care clinics across both Taiwan and China. The company delivers a comprehensive range of ophthalmic services, encompassing advanced surgical interventions and treatments for various ocular conditions. Its surgical specialties include laser vision correction for common refractive errors such as myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related vision decline). They also perform intraocular lens procedures for presbyopia and cataracts, employing advanced techniques like phacoemulsification and femtosecond laser surgery. Beyond surgical solutions, Universal Vision addresses a wide spectrum of eye health concerns, offering services for myopia control, dry eye syndrome, retinal detachment, macular degeneration, strabismus (crossed eyes), amblyopia (lazy eye), and numerous other ophthalmic ailments. The company further provides a diverse array of vision products and optical aids, including various eyeglass frames, specialized multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, and both conventional and colored contact lenses. Nutritional eye supplements are also available. Additional offerings include oculoplastic and micro cosmetic eye surgery, alongside bespoke aesthetic medicine consultations. Furthermore, Universal Vision engages in optometric services, hospital administration, technical advisory roles, and the distribution and rental of medical equipment.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.25% | -3.33% | +0.77% | -5.43% | -16.08% | -10.62% | -27.70% | -63.93% | -49.92% | +543.17% | +192.54% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-0.6% Q1'26: -3.0% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-1.8% Q1'26: -22.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+25.3% Q1'26: +30.9% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+32.8% ★ Q1'26: +30.6% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+34.7% ★ Q1'26: +34.7% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.8% Q1'26: +2.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.77× ★ Q1'26: 0.80× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.04B
est.
|
1.04B
est.
|
4.91B
est.
|
5.07B
est.
|
1.42B
est: 1.41B (+0.8%)
|
2.05B
est: 2.06B (-0.4%)
|
2.63B
est: 2.62B (+0.3%)
|
3.49B
est: 3.47B (+0.7%)
|
4.08B
est: 4.08B (+0.0%)
|
4.23B
est: 4.24B (-0.4%)
|
4.20B
est: 4.20B (+0.0%)
|
4.34B
4.32B – 4.37B
+3.3% YoY
|
4.44B
4.43B – 4.45B
+2.3% YoY
|
| EBITDA |
444.77M
est.
|
444.77M
est.
|
2.11B
est.
|
2.17B
est.
|
372.70M
est: 603.41M (-38.2%)
|
877.04M
est: 883.51M (-0.7%)
|
1.10B
est: 1.12B (-2.6%)
|
1.48B
est: 1.49B (-0.6%)
|
1.78B
est: 1.75B (+1.8%)
|
1.86B
est: 1.73B (+7.2%)
|
1.38B
est: 1.72B (-19.7%)
|
1.77B
1.77B – 1.78B
+3.3% YoY
|
1.82B
1.81B – 1.82B
+2.3% YoY
|
| EBIT |
322.49M
est.
|
322.49M
est.
|
1.53B
est.
|
1.58B
est.
|
247.04M
est: 437.51M (-43.5%)
|
613.07M
est: 640.60M (-4.3%)
|
776.27M
est: 815.58M (-4.8%)
|
1.11B
est: 1.08B (+2.5%)
|
1.33B
est: 1.27B (+5.2%)
|
1.34B
est: 1.53B (-12.4%)
|
1.38B
est: 1.51B (-8.8%)
|
1.56B
1.55B – 1.57B
+3.3% YoY
|
1.60B
1.59B – 1.60B
+2.3% YoY
|
| Net Income |
85.09M
est.
|
85.09M
est.
|
449.28M
est.
|
132.82M
est.
|
238.01M
est: 231.44M (+2.8%)
|
483.21M
est: 499.22M (-3.2%)
|
595.43M
est: 573.77M (+3.8%)
|
850.53M
est: 821.99M (+3.5%)
|
1.05B
est: 1.07B (-2.0%)
|
1.06B
est: 1.10B (-3.1%)
|
1.05B
est: 1.05B (+0.0%)
|
1.16B
1.15B – 1.16B
+9.6% YoY
|
1.22B
1.22B – 1.22B
+5.6% YoY
|
| SGA |
311.85M
est.
|
311.85M
est.
|
1.48B
est.
|
1.52B
est.
|
570.02M
est: 423.07M (+34.7%)
|
670.63M
est: 619.46M (+8.3%)
|
867.59M
est: 788.66M (+10.0%)
|
1.05B
est: 1.04B (+0.8%)
|
1.13B
est: 1.23B (-7.7%)
|
1.13B
est: 997.98M (+13.5%)
|
—
est: 988.60M (-100.0%)
|
1.02B
1.02B – 1.03B
+3.3% YoY
|
1.04B
1.04B – 1.05B
+2.3% YoY
|
| EPS |
1.00
est.
|
1.00
est.
|
5.29
est.
|
1.56
est.
|
2.81
est: 2.72 (+3.2%)
|
5.71
est: 5.88 (-2.8%)
|
7.03
est: 6.75 (+4.1%)
|
10.04
est: 9.68 (+3.8%)
|
12.34
est: 12.55 (-1.6%)
|
12.59
est: 12.83 (-1.8%)
|
12.31
est: 12.31 (+0.0%)
|
13.48
13.48 – 13.49
+9.6% YoY
|
14.24
14.19 – 14.29
+5.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 17.7K | 0.42% |
| 2 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.01% | 17.1K | 0.35% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 17.7K | 0.56% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 624.6K | 0.06% |
| 5 | Avantis Emerging Markets Value ETF AVES | 0.00% | 53.2K | 0.36% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 315.8K | 0.39% |
| 7 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.00% | 13.3K | 0.33% |
| 8 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 62.0K | 0.46% |
| 9 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 13.3K | 0.44% |
| 10 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 203.4K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhenghong Lu | General Manager | 14M | male |
| Pi-Jung Lin | Founder, President, Chief Technology Officer & Representative Director | 3M | male |
| Chien-Hsiang Yu | Director of Marketing Division | — | male |
| Shu-Hsin Lin | Chief Auditor of Audit Office | — | female |
| Yu-chi Chan | Director of Human Resources & Administration Division | — | male |
| Yujiao Sun | Director of Finance & Accounting | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3218.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
